title: Use of arsenic trioxide in secondary acute promyelocytic leukemia developing after treatment of multiple sclerosis with mitoxantrone.
authors.forename: Emanuele
authors.initials: E
authors.lastname: Ammatuna
authors.forename: Enrico
authors.initials: E
authors.lastname: Montefusco
authors.forename: Matteo
authors.initials: M
authors.lastname: Pacilli
authors.forename: Mariadomenica
authors.initials: M
authors.lastname: Divona
authors.forename: Davide
authors.initials: D
authors.lastname: Ardiri
authors.forename: Diego
authors.initials: D
authors.lastname: Centonze
authors.forename: Francesco
authors.initials: F
authors.lastname: Lo-Coco
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D000077237:Arsenic Trioxide; D001152:Arsenicals / Q000627:therapeutic use; D004791:Enzyme Inhibitors / Q000494:pharmacology; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000139:chemically induced* / Q000150:complications* / Q000188:drug therapy*; D008297:Male; D008942:Mitoxantrone / Q000009:adverse effects*; D009103:Multiple Sclerosis / Q000150:complications / Q000188:drug therapy*; D010087:Oxides / Q000627:therapeutic use; D012074:Remission Induction; D059005:Topoisomerase II Inhibitors; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D001152:Arsenicals; D004791:Enzyme Inhibitors; D010087:Oxides; D059005:Topoisomerase II Inhibitors; D008942:Mitoxantrone; D000077237:Arsenic Trioxide